The TMB Test employs next-generation sequencing (NGS) technology to analyze the tumor genome and detect somatic mutations. It assesses the total number of non-synonymous somatic mutations, including base substitutions, insertions, and deletions, across a broad range of genes. By quantifying the mutation burden, the test provides a measure of genomic instability and potential neoantigen formation in the tumor.